Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)

Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: Results of a pooled analysis of non-interventional studies

(2015) Laurence Albiges et al.   EUROPEAN JOURNAL OF CANCER

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Toni K. Choueiri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 

(2014) B. Escudier et al.   ANNALS OF ONCOLOGY

Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma

(2014) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

(2011) Viktor Grünwald et al.   EUROPEAN JOURNAL OF CANCER

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study

(2011) E. Calvo et al.   EUROPEAN JOURNAL OF CANCER

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER